key: cord-0978333-jeuwdsok authors: Flacco, M. E.; Acuti Martellucci, C.; Bravi, F.; Parruti, G.; Mascitelli, A.; Mantovani, L.; Manzoli, L. title: SARS-CoV-2 lethality decreased over time in two Italian Provinces date: 2020-05-24 journal: nan DOI: 10.1101/2020.05.23.20110882 sha: b24bc39bece674481c7d694fcfb3454d7570ea42 doc_id: 978333 cord_uid: jeuwdsok Background Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available. This retrospective cohort study aimed to evaluate whether SARS-CoV-2 case-fatality rate decreased with time, adjusting for main potential confounders. Methods and findings We included all SARS-CoV-2 infected subjects diagnosed in Ferrara and Pescara provinces, Italy. Information were collected from local registries, clinical charts, and electronic health records. We compared the case-fatality rate of the subjects diagnosed during April and March, 2020. We used Cox proportional hazards analysis and random-effect logistic regression, adjusting for age, gender, hypertension, type II diabetes, major cardiovascular diseases (CVD), chronic obstructive pulmonary diseases (COPD), cancer and renal disease. The sample included 1946 subjects (mean age 58.8y; 45.7% males). 177 persons deceased, after a mean of 11.7 days of follow-up. From March to April, the case-fatality rate significantly decreased in the total sample (10.8% versus 6.0%; p<0.001), and in any subgroup of patients. Large reductions of the lethality were observed among the elderly (from 30.0% to 13.4%), and subjects with hypertension (23.0% to 12.1%), diabetes (30.3% to 8.4%), CVD (31.5% to 12.1%), COPD (29.7% to 11.4%), and renal disease (32.3% to 11.5%). In April, the adjusted hazard ratio of death was 0.42 (95% Confidence Interval: 0.29-0.60). The mean age of those who died substantially increased from March (77.9y) to April (86.9y). Conclusions In this sample, SARS-CoV-2 case-fatality rate decreased considerably over time, supporting recent claims of a substantial improvement of SARS-CoV-2 clinical management. The findings are inevitably preliminary and require confirmation. As of May 18, 2020, SARS-CoV-2 pandemic has caused 320,000 deaths worldwide [1] , with largely 72 discrepant case-fatality rates across countries (from <1% to 16%) [2] , likely due to differences in population 73 age structure [3, 4] , variations in testing policies and case recording [5] , and/or preparedness of the 74 healthcare system, which in turn is affected by the intensity of the spread [4, 5] . Since the start of the pandemic, Italy has been among the countries with the highest death toll, with more 76 than 32,000 recorded deaths [1] , and an estimated case-fatality rate of 14% [2] , which peaked at 20% among 77 the citizens aged ≥ 80 years [6] . In the last few weeks, some clinicians suggested that SARS-CoV-2 lethality decreased considerably, mostly 79 as a consequence of more tailored therapeutic approaches [7] [8] [9] [10] [11] . Although the claims were made by expert 80 physicians, actively engaged in the care of infected patients, the available evidence is anecdotal or based 81 upon case-studies. We analysed the data of all infected cases in two Italian Provinces to evaluate whether SARS-CoV-2 case-83 fatality rate decreased with time, adjusting for main potential confounders. This retrospective cohort study included all subjects infected with SARS-CoV-2, diagnosed in the Provinces 87 of Ferrara and Pescara, between March 3 (the onset date of the first cases), and April 25, 2020. All 88 participants were followed up to May 5, 2020. All infections were diagnosed by the central laboratories of 89 Ferrara University Hospital or Pescara Hospital through RT-PCR (Reverse transcription polymerase chain 90 reaction) test on nasopharyngeal swabs, and were confirmed by the Italian National Institute of Health. Information on age, gender, and pre-existing conditions of all participants were collected from local 92 registries, clinical charts (for hospitalized patients), and through data-linkage with hospital discharge 93 abstracts (Italian SDO) and the National database of drug prescription. Electronic databases were queried 94 from the day of the diagnosis until January 1st, 2015. All data have been revised manually by two physicians 95 (LM and MEF) , and the following conditions have been included in the analyses: hypertension, type II 96 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020 . . https://doi.org/10.1101 diabetes, major cardiovascular diseases (heart failure, myocardial infarction and stroke -CVD), chronic 97 obstructive pulmonary diseases (COPD, bronchitis, pneumonia, asthma, and emphysema), malignant tumors 98 and renal disease. The study complies with the Declaration of Helsinki, the research protocol was approved by the Ethics 100 Committee of the Emilia-Romagna Region (code 287, approved on March 24, 2020), and the requirement for 101 informed consent was waived because of the retrospective and pseudo-anonymized nature of the data. We compared the case-fatality rate (fatal / confirmed cases) during the first 29 days after the index day (from 105 March 3 to March 31) with that of the second half of the period (days 30-53; from April 1 to April 25). The 106 differences between the two periods were initially evaluated using t-test for continuous variables, and chi-107 squared test for categorical ones. The potential independent predictors of death were then evaluated using 108 Cox proportional hazards analysis (using the data censored at May 5, to include ≥ 10 days of follow-up). All 109 covariates were included a priori in the model in their original form, with the exception of age, which was 110 treated as either continuous or ordinal, to explore the association between the outcome and several age 111 classes. Schoenfeld's test was used to assess the validity of proportional hazards assumption, and Nelson-112 Aalen cumulative hazard estimates to check the validity of constant incidence ratios during the follow-up 113 [12] . Using the data censored at 20 days of follow-up, a random-effect logistic regression was also fit, with 114 province as the cluster unit. The same above criteria were used to build the final model. Missing data were 115 <5% in all primary analyses; therefore, no missing imputation technique was adopted. Statistical significance 116 was defined as a two-sided p-value<0.05, and all analyses were carried out using Stata, version 13.1 (Stata 117 Corp., College Station, TX, 2014). The sample consisted of 1946 subjects (mean age 58.8y; 45.7% males); of them, 31.2% were hypertensive, 121 12.3% diabetics, and 16.6% with CVD. Some of the characteristics of the sample significantly varied from 122 March to April. Infected subjects were older by 5.6 years, and the proportion of females, diabetics, subjects 123 with CVD and renal diseases significantly increased (Table 1) . 124 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.23.20110882 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.23.20110882 doi: medRxiv preprint As shown in Table 2 , a reduction of SARS-CoV-2 lethality was observed in any age-class and any category 142 of risk. The decrease was however larger among the subjects at higher risk of death: with the lethality 143 dropping from 23.4% to 6.1% in the age-class 70-79y, and from 36.3% to 16.1% among the elderly (80+ 144 years); both p<0.05. Similar reductions of the case-fatality rate were observed among the subjects with 145 hypertension (from 23.0% to 12.1%), diabetes (from 30.3% to 8.4%), CVD (from 31.5% to 12.1%), COPD 146 (from 29.7% to 11.4%), and renal disease (from 32.3% to 11.5%; all univariate p-values<0.05). 152 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.23.20110882 doi: medRxiv preprint any subset of the sample, with HRs ranging from 0.20 among the subjects with renal disease, up to 0.51 162 among those aged 80 years or more ( Table 2 ). The results of the random-effect logistic regression did not 163 vary: overall, the adjusted odds ratio of death at 20 days was 0.29 (95% CI: 0.19-0.45; p<0.001) for those 164 diagnosed in April, as compared to the subjects detected in March. This study provides the first evidence of a considerable decrease of SARS-CoV-2 case-fatality rate over 168 time. From March to April 2020, the death rate decreased by more than 50% in all age-classes, being larger 169 among the subjects with the highest risk of death because of comorbidities [13, 14] . This finding was 170 confirmed in all multivariable analyses, adjusting for several potential confounders. It is complex to discern which could be the potential reasons for the observed, entirely novel findings. The 172 first, most obvious explanation, is that the healthcare system might have been overcrowded during the 173 epidemic peak in March, with a loss of efficacy [15] . This is however very unlikely to apply to the present 174 sample, because SARS-CoV-2 infection rates were relatively low -and never exceeded the capacity of the (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10. 1101 considerably improving the clinical course of 11 ]. In the two provinces under investigation, 183 the treatment is currently based upon antiviral agents (Chloroquine / Hydroxychloroquine or Lopinavir / 184 Ritonavir), intensive respiratory support [18, 19] , and, from the latest days of March, low molecular weight 185 heparin and monoclonal antibodies against inflammatory cytokines (e.g. Tocilizumab), which showed some 186 preliminary, promising results [18, [20] [21] [22] [23] . Given that available data are anecdotal, only the results of the 187 several randomized trials that are being conduced on the above treatments [18], will permit to discern which 188 approach, and to what extent, contributed to the improvement of SARS-CoV-2 infection prognosis. The main limitations of the study are the inclusion of only two provinces from a single country, and the lack 190 of data on body mass index, which is emerging as significant predictor of death from 25] . In conclusion, the present study provided evidence of a significant, considerable decrease of SARS-CoV-2 192 case-fatality rate between March and April, 2020, supporting preliminary claims on a substantial 193 improvement of the therapeutic approaches. The findings are inevitably preliminary and require confirmation 194 from further datasets and ongoing randomized trials. 195 196 197 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020 . . https://doi.org/10.1101 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020 . . https://doi.org/10.1101 233 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10.1101/2020.05.23.20110882 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 24, 2020. . https://doi.org/10. 1101 COVID-19 Coronavirus Outbreak Demographic science aids in 214 understanding the spread and fatality rates of COVID-19 What Other Countries Can Learn From Italy During the 218 COVID-19 Pandemic Covid-19: A Dynamic Analysis of Fatality Risk in Italy Case-Fatality Rate and Characteristics of Patients Dying in 223 Relation to COVID-19 in Italy Cardiovascular Disease, Drug Therapy, and 247 Mortality in Covid-19 Intensive care management of 250 coronavirus disease 2019 (COVID-19): challenges and recommendations COVID-19 Italia -Monitoraggio della situazione 2020 No evidence for distinct types in the evolution of 257 SARS-CoV-2 Pharmacologic Treatments for Coronavirus 19 Impact of low dose 266 tocilizumab on mortality rate in patients with COVID-19 related pneumonia Use of subcutaneous 270 tocilizumab in patients with COVID-19 pneumonia LMWH in adult COVID-19 patients [Eparine a basso peso molecolare nei pazienti adulti con 273 COVID-19 American Society of H. COVID-19 and VTE/Anticoagulation High prevalence of 276 obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical 277 ventilation